Pimodivir

Pimodivir

Clinical data
Trade names	Pimodivir
Legal status
Legal status	US: Investigational New Drug
Identifiers
IUPAC name (2S,3S)-3-[[5-fluoro-2-(5-fluoro-1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-4-yl]amino]bicyclo[2.2.2]octane-2-carboxylic acid
JSmol)	Interactive image
SMILES O=C(O)[C@H]1C2CCC(CC2)[C@@H]1Nc1nc(-c2c[nH]c3ncc(F)cc23)ncc1F
InChI InChI=1S/C20H19F2N5O2/c21-11-5-12-13(7-24-17(12)23-6-11)18-25-8-14(22)19(27-18)26-16-10-3-1-9(2-4-10)15(16)20(28)29/h5-10,15-16H,1-4H2,(H,23,24)(H,28,29)(H,25,26,27)/t9?,10?,15-,16-/m0/s1 Key:JGPXDNKSIXAZEQ-SBBZOCNPSA-N

Pimodivir (VX-787, JNJ-63623872) is an antiviral drug which was developed as a treatment for influenza. It acts as an inhibitor of influenza virus polymerase basic protein 2, and has shown promising results in Phase II clinical trials.^[1][2][3] However, in late 2021, Janssen announced that the clinical development of pimidivir had been halted due to lack of benefit over standard of care.^[4]

See also

• Baloxavir marboxil
• Favipiravir
• Galidesivir
• Nitazoxanide
• Oseltamivir
• Peramivir
• Remdesivir
• Ribavirin
• Triazavirin
• Umifenovir
• Zanamivir

References